Stockreport
Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So [Seeking Alpha]
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
MIRM's commercial products are projected to generate $500–510m in 2025, led by Livmarli, with strong year-on-year revenue growth and upgraded guidance. The Bluejay Therapeutics acquisition adds brelovitug, a late-stage HDV asset, expanding MIRM's pipeline to four potential registrational readouts within 18 months. I maintain a Buy rating, citing robust pipeline momentum and upside potential, but remain cautious on competitive threats and blockbuster revenue targets. Klaus Vedfelt/DigitalVision via Getty Images Mirum Investment Overview - Why I Flipped From A Sell To A Buy Rating In March In March this year, I flipped my rating on Mirum Pharmaceuticals, Inc. ( MIRM ) stock from the More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Gro
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 [Seeking Alpha][Seeking Alpha]
- Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Citizens Jmp from $95.00 to $140.00. They now have a "market outperform" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX[Business Wire]
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..[MarketBeat]
- More
MIRM
SEC Filings
SEC Filings
- 12/22/25 - Form 144
- 12/19/25 - Form 4
- 12/19/25 - Form 144
- MIRM's page on the SEC website
- More